Nature reviews. Drug discovery, 2010-01, Vol.9 (1), p.17-18
2010
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Pazopanib
- Ist Teil von
- Nature reviews. Drug discovery, 2010-01, Vol.9 (1), p.17-18
- Ort / Verlag
- London: Nature Publishing Group UK
- Erscheinungsjahr
- 2010
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In October 2009, pazopanib (Votrient; GlaxoSmithKline) — a multikinase inhibitor with targets that include vascular endothelial growth factor receptors — was approved by the US FDA for the treatment of advanced renal cell carcinoma. Pazopanib
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1474-1776eISSN: 1474-1784DOI: 10.1038/nrd3073Titel-ID: cdi_proquest_journals_223605778
- Format
- –
- Schlagworte
- 631/154/155, 692/699/67/1059/602, 692/699/67/589/1588/1351, Antineoplastic Agents - adverse effects, Antineoplastic Agents - pharmacology, Antineoplastic Agents - therapeutic use, Biomedical and Life Sciences, Biomedicine, Biotechnology, Cancer Research, Carcinoma, Renal Cell - drug therapy, Carcinoma, Renal Cell - physiopathology, Clinical Trials as Topic, Drug Delivery Systems, fresh-from-the-pipeline, Humans, Kidney Neoplasms - drug therapy, Kidney Neoplasms - physiopathology, Licensing, certification and accreditation, Medicinal Chemistry, Molecular Medicine, Pazopanib, Pharmaceutical industry, Pharmacology/Toxicology, Product development, Protein Kinase Inhibitors - adverse effects, Protein Kinase Inhibitors - pharmacology, Protein Kinase Inhibitors - therapeutic use, Pyrimidines - adverse effects, Pyrimidines - pharmacology, Pyrimidines - therapeutic use, Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors, Sulfonamides - adverse effects, Sulfonamides - pharmacology, Sulfonamides - therapeutic use